Related Experiment Video
Updated: May 19, 2026
07:08
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers
Niklas Mattsson1, Ulf Andreasson, Maria C Carrillo
1Clinical Neurochemistry Laboratory, Institute of Neuroscience & Physiology, Department of Psychiatry & Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Mölndal, Sweden. niklas.mattsson@neuro.gu.se
Biomarkers in Medicine
|August 25, 2012
Summary
Proficiency testing programs for cerebrospinal fluid (CSF) biomarkers are established for Alzheimer's disease diagnosis. These programs are crucial for standardizing measurements, enabling widespread clinical use of CSF biomarkers.
Area of Science:
- Neurology
- Biochemistry
- Clinical Diagnostics
Background:
- Cerebrospinal fluid (CSF) biomarkers are vital for Alzheimer's disease (AD) diagnosis in research and clinical settings.
- Laboratory variability in CSF biomarker measurements can impact diagnostic accuracy and comparability.
Purpose of the Study:
- To review the outcomes of recent pilot proficiency testing programs for CSF biomarkers.
- To outline current standardization initiatives for CSF biomarker analysis.
Main Methods:
- Analysis of results from pilot proficiency testing programs involving multiple laboratories.
- Description of ongoing efforts to standardize CSF biomarker measurement techniques.
Main Results:
- Global proficiency testing for CSF biomarkers is now fully established.
- Proficiency testing effectively monitors laboratory variability in CSF biomarker analysis.
Conclusions:
- Established global proficiency testing is essential for standardizing CSF biomarker measurements.
- Standardization through proficiency testing is a prerequisite for the broad clinical implementation of CSF biomarkers in Alzheimer's disease diagnostics.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.